People · Operator
Named in public records as an officer, director or promoter · active 2013–2025 · Biotechnology, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Atsena Therapeutics, Inc. | — | Biotechnology | Series C | $146.0M | $605.7M | 2020 |
| Ribometrix, Inc. | — | Pharmaceuticals | Series A | $18.5M | $464.6M | 2018 |
| Altis Biosystems, Inc. | — | Biotechnology | Seed | $6.6M | $6.8M | 2025 |
| Curoverse, Inc. | — | Other | Seed | $3.7M | $9.3M | 2013 |
Michael Dial at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Dial on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Ross | 1 | 18 |
| Joshua Resnick | 1 | 12 |
| David Martirano | 1 | 11 |
| James Healy | 1 | 8 |
| Michael Solomon | 1 | 7 |
| William Marshall | 1 | 6 |
| Jeremy Allaire | 1 | 5 |
| Christopher Sims | 1 | 5 |
| Norbert Riedel | 1 | 4 |
| JOHN GUSTOFSON | 1 | 3 |
| Benjamin Scruggs | 1 | 3 |
| Jacqueline Grant | 1 | 3 |
| Susan Mahony | 1 | 2 |
| Hakan Goker | 1 | 2 |
| Joseph McMahon | 1 | 2 |
| Mike Dial | 1 | 2 |
| Benjamin Yerxa | 1 | 2 |
| Patrick Ritschel | 1 | 2 |
| Katherine Warner | 1 | 1 |
| Ward Vandewege | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.